

1 **Population-based estimates of hepatitis E virus associated mortality in**
2 **Bangladesh**

3
4 Repon C Paul^{1,2}, Heather F Gidding^{3,4}, Arifa Nazneen¹, Kajal C Banik¹, Shariful Amin Sumon¹,
5 Kishor K Paul^{1,3}, Arifa Akram⁵, M Salim Uzzaman⁵, Alexandra Tejada-Strop⁶, Saleem Kamili⁶,
6 Stephen P Luby⁷, Andrew Hayen⁸, Emily S Gurley⁹

7
8 ¹icddr,b, Dhaka, Bangladesh

9 ²National Perinatal Epidemiology and Statistics Unit and Centre for Big Data Research in Health,
10 Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia

11 ³School of Population Health, Faculty of Medicine and Health, University of New South Wales,
12 Sydney, NSW, Australia

13 ⁴Health and Clinical Analytics Lab, Sydney School of Public Health Faculty of Medicine and
14 Health, University of Sydney

15 ⁵Institute of Epidemiology, Disease Control and Research, Bangladesh

16 ⁶Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia

17 ⁷Infectious Diseases and Geographic Medicine, Stanford University, Stanford, California, United
18 States of America

19 ⁸School of Public Health, University of Technology Sydney, Sydney, Australia

20 ^{1,9}Johns Hopkins Bloomberg School of Public Health, Baltimore, USA

21

22

23

24

25 Funding: The Centers for Disease Control and Prevention (CDC), United States

26

27 **Word Count:** Abstract: 246; Manuscript: 3,487; Table: 4; Map:1; Appendix:2

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 **Abstract**

29 Background

30 Hepatitis E virus (HEV) is endemic in many resource-poor countries. Despite an available
31 vaccine, data on HEV-associated mortality are scarce, hindering informed decisions. This study
32 aims to estimate the population-based rate of HEV-specific mortality in Bangladesh.

33 Methods

34 During December 2014-September 2017, we conducted surveillance in six tertiary hospitals in
35 Bangladesh. Patients aged ≥ 14 years with acute jaundice were recruited, tested for IgM anti-
36 HEV, and followed up post-discharge. A mortality survey in the hospital catchment areas
37 identified deaths associated with acute jaundice, including maternal, stillbirths and neonatal
38 deaths delivered by a mother with acute jaundice during pregnancy, confirmed by two
39 independent physicians reviewing verbal autopsy data.

40 Findings

41 Out of 1,925 patients with acute jaundice identified and enrolled in the surveillance hospitals,
42 302 died, with 28 (9%) testing positive for IgM anti-HEV. In the hospital catchment areas, the
43 team identified 587 jaundice-associated deaths, including 25 maternal deaths. Combining
44 hospital-based surveillance and mortality survey data, the study estimated 986 (95% CI: 599-
45 1338) HEV-associated deaths annually among individuals aged ≥ 14 years in Bangladesh,
46 including 163 (95% CI: 57-395) maternal deaths. Additionally, 279 (95% CI: 101-664) stillbirths
47 and 780 (95% CI: 365-1,297) neonatal deaths were attributed to HEV infection annually.

48 Interpretation

49 Prior Global Burden of Disease studies presented wildly varying modeling estimates of HEV-
50 associated annual deaths, ranging from 50,000 in 2013 to 1,932 in 2019. This study is the first to
51 directly measure population-based estimates of mortality in Bangladesh, which can be used to
52 determine the cost-effectiveness of hepatitis E vaccination and other interventions.

53 **Introduction**

54 Hepatitis E virus (HEV) causes acute liver infection; transmission of genotypes 1 and 2 occurs
55 among humans through the fecal-oral route, while genotypes 3 and 4 are zoonotic and primarily
56 infect humans through the consumption of undercooked meat^{1,2}. In low- and middle-income
57 countries, where fecal contamination of drinking water is common, genotypes 1 and 2 pose
58 significant public health concerns^{1,2}. In these settings, where HEV infection is a leading cause of
59 acute viral hepatitis¹, population-based studies estimating the disease burden are scarce due to
60 inadequate surveillance systems and limited vital registration of cause-specific deaths.

61 Existing estimates of the burden of HEV infection rely on mathematical models, including the
62 Global Burden of Disease effort were built upon several strong assumptions^{3,4}. These
63 assumptions include predicting the proportion of people with antibodies against HEV who
64 develop clinical disease, comparing HEV-associated mortality between HEV endemic low- and
65 middle-income countries and high-income countries with effective vital registration, and
66 extrapolating the likelihood of death among hospitalized hepatitis E patients to non-hospitalized
67 severe cases. Notably, the global annual HEV-related death toll projections by these models
68 have varied significantly, from 70,000 in 2005 to 1,932 in 2019³⁻⁷.

69 HEV infection is preventable through sanitation, adherence to safe food and water precautions,
70 and potentially vaccination. Two hepatitis E vaccine candidates, following non-human primate
71 experiments, progressed to clinical trials in humans^{8,9}. One of these vaccines, HEV 239, was
72 licensed in China in 2011 and in Pakistan in 2020 for use among residents aged ≥ 16 years¹⁰. A
73 major barrier to recommending the vaccine in routine national vaccination programs in other
74 countries, however, is the lack of confidence in the wide-ranging burden of disease estimates
75 and a dearth of population-based measurements of HEV-associated mortality¹¹.

76 During 2014-2017, the International Centre for Diarrhoeal Disease Research, Bangladesh
77 (icddr,b) in collaboration with the Institute of Epidemiology, Disease Research and Control
78 (IEDCR) of the Government of Bangladesh and the Centers for Disease Control and Prevention
79 (CDC), United States conducted a hospital-based acute jaundice surveillance study in Bangladesh
80 to identify patients admitted with acute jaundice¹². However, estimating mortality burden from
81 hospital-based studies may not fully represent the general population due to healthcare access
82 disparities in many low- and middle-income countries¹³. We conducted a mortality survey in the

83 catchment areas of surveillance hospitals and calculated population-based estimates of HEV-
84 specific mortality by combining data from the hospital-based surveillance and mortality survey.

85 **Methods**

86 **Hospital-based acute jaundice surveillance**

87 Detailed information on hospital-based acute jaundice surveillance is available elsewhere¹². In
88 summary, a study spanning December 2014 to September 2017 investigated acute jaundice in
89 six randomly selected tertiary hospitals across five divisions in Bangladesh (Figure 1). Patients
90 aged ≥ 14 years, exhibiting acute jaundice (defined as new onset of yellow sclera or skin during
91 the past 3 months, persisting on admission day), were recruited. Blood samples from all
92 recruited patients were tested for IgM anti-HEV using an enzyme-linked immunosorbent assay
93 (ELISA) with a sensitivity of 98-100% and a specificity of 95-100% (Beijing Wantai Biologic
94 Pharmacy Enterprise Co., Ltd, Beijing, China). Patients positive for IgM anti-HEV antibodies were
95 considered to have acute HEV infection.

96 Enrolled patients were followed during their hospitalization and for 3 months post-discharge to
97 ascertain vital status and pregnancy outcomes for pregnant women. However, post-discharge
98 follow-up was not possible for patients admitted after June, 2017, as surveillance ended on
99 September 30, 2017.

100 **Mortality survey in hospital catchment areas**

101 **Selection of hospital catchment areas**

102 The study team reviewed the hospital records of jaundice patients admitted from January to
103 June 2014 to identify the primary catchment areas of each surveillance hospital, defined as the
104 sub-districts where 75% of the admitted jaundice patients resided. Applying this criterion, we
105 selected 63 sub-districts across 18 districts (out of 64) in Bangladesh. Sub-districts in
106 Bangladesh consist of a median of 15 unions (IQR: 7-20 unions), which are the smallest
107 administrative units in Bangladesh with an average population of 26,000 people¹⁴.

108 **Selection of survey clusters**

109 For rare events, such as maternal deaths, a large sample size is required to estimate death rates
110 with acceptable precision¹⁵. Therefore, we assumed that our study, designed to estimate
111 maternal mortality associated with HEV infection with acceptable precision, would also provide
112 sufficient power for estimating mortality in adults, neonatal deaths, and stillbirths associated
113 with HEV infection. The sample size for estimating maternal mortality was determined using the
114 formula for estimating proportions¹⁶, assuming that 10% of maternal deaths are associated with
115 HEV infection¹⁷. With a precision of 5%, a 95% confidence level, and a design effect of 2.0, we
116 calculated a required sample size of 277 maternal deaths in the surveillance hospitals'
117 catchment areas. To achieve this size, we conducted the survey in 91 unions, collecting
118 mortality data for the prior three years. Assuming a maternal mortality ratio of 194 per 100,000
119 live births¹⁸ and the crude live birth rate of 22.2 per 1,000 population¹⁹, we randomly selected
120 91 unions from the defined hospital catchment areas using a probability proportional to size
121 sampling approach²⁰.

122 **Mortality Survey**

123 Between November 2014 and February 2017, a mortality survey was undertaken across 91
124 unions to identify deaths associated with jaundice. The survey also identified stillborn babies
125 and live-born babies who died during neonatal period delivered by mothers with jaundice
126 during pregnancy, and all-cause maternal deaths (Figure 1). Jaundice was defined as having new
127 onset of either yellow sclera or skin during the illness prior to death. A neonatal death was
128 defined as occurring within the first 28 days of life, while a stillbirth was defined as a baby
129 delivered by a mother after 28 weeks of gestation with no signs of life²¹. Maternal death was
130 defined as the death of a woman while pregnant or within 42 days of pregnancy termination,
131 excluding unintentional injuries or unrelated incidental causes²¹.

132 In urban communities, we conducted a house-to-house survey to identify deaths, whereas in
133 rural communities, we used a low-cost community knowledge approach (further detailed in²²).
134 Out of 91 unions, 25 (27%) were urban, closely matching the urban population percentage
135 (23%) in the 2011 Bangladesh Population Census²³. For identified jaundice-associated deaths
136 and all-cause maternal deaths, a verbal autopsy questionnaire was administered to collect
137 detailed information on the signs, symptoms and duration of illness preceding death to
138 determine the underlying and immediate cause of death. Two physicians independently

139 assessed VA questionnaires, assigning ICD-10 cause of death codes. Discordant cases prompted
140 discussion for consensus, with a third physician intervening if disagreement persisted.

141 **Data analysis**

142 We calculated the HEV-associated mortality rate for individuals aged ≥ 14 years, maternal
143 mortality ratio, and stillbirth and neonatal mortality rate for all catchment areas combined. The
144 population in 2014 served as our mid-year reference, considering our data collection spanned
145 from November 2014 and February 2017 (about 60% collected in 2015) and we collected
146 mortality data for the prior three years. For rural unions, we projected the population for 2014
147 based on the 2011 Bangladesh census, considering an annual growth rate of 1.37% (Appendix
148 1)²⁴. For the urban unions, we counted the household population at the time of mortality
149 survey. We projected the population aged ≥ 14 years, assuming 67.7% of total population in
150 2014 were aged ≥ 14 years²⁴. The number of live births in 2014 was estimated assuming a crude
151 birth rate of 22.2 per 1,000 population as per the Bangladesh Demographic and Health Survey,
152 2014¹⁹.

153 Although we collected information on both chronic and acute jaundice associated deaths in the
154 mortality survey, for incidence calculation only deaths associated with acute jaundice were
155 considered, defined as new onset of yellow eyes or skin within the 3 months prior to death.
156 Because we used the same case definition of acute jaundice in hospitals and hospital catchment
157 areas, we assumed that the illness in people who died in the catchment areas was similar to
158 those who died in the study hospitals. To calculate HEV associated mortality in the hospital
159 catchment areas, we multiplied the estimate for jaundice-associated mortality in the hospital
160 catchment areas by the proportion of HEV infections among acute jaundice deaths in the
161 surveillance hospitals.

162 Recognizing HEV's additional risk during pregnancy^{1,2} and its varying age-specific infection rates
163 and severity²⁵, we separately projected HEV-associated deaths among pregnant women and
164 non-pregnant persons aged ≥ 14 years (14-44 years, 45-59 years, and ≥ 60 years). The projected
165 deaths in both groups were aggregated to estimate the total number of HEV-associated deaths
166 in the hospital catchment areas. We used the following equation to estimate mortality
167 associated with HEV in the hospital catchment areas:

168 HEV associated mortality for the population aged ≥ 14 years =

169
$$\frac{D_m \frac{E_m}{J_m} + \sum D_i \frac{E_i}{J_i}}{P * 3} \times 100,000$$

170 where,

171 P = Estimated population aged ≥ 14 years in the study areas in 2014

172 D_m = Number of maternal deaths associated with acute jaundice identified in the three-year
173 period in the study areas

174 J_m = Number of maternal deaths associated with acute jaundice in the surveillance hospitals

175 E_m = Number of laboratory-confirmed HEV cases among maternal deaths associated with acute
176 jaundice in the surveillance hospitals

177 D_i = Number of age-specific non-maternal deaths associated with acute jaundice identified in
178 the three-year period in the study areas

179 J_i = Number of age-specific non-maternal deaths associated with acute jaundice in the
180 surveillance hospitals

181 E_i = Number of age-specific laboratory-confirmed HEV cases among non-maternal deaths
182 associated with acute jaundice in the surveillance hospitals

183
184 Similarly, the following formulas were used to calculate HEV associated maternal mortality,
185 neonatal mortality and stillbirth:

186 Maternal mortality ratio associated with HEV = $\left(\frac{D_m/3}{B}\right) \left(\frac{E_m}{J_m}\right) \times 100,000$

187 Stillbirth rate associated with HEV = $\left(\frac{S/3}{B}\right) \left(\frac{S_e}{S_j}\right) \times 100,000$

188 Neonatal mortality rate associated with HEV = $\left(\frac{N/3}{B}\right) \left(\frac{N_e}{N_j}\right) \times 100,000$

189 where, D_m , J_m and E_m are defined above and:

190 B = Estimated live births in the study areas in 2014

191 S = Number of stillbirths delivered by a mother with acute jaundice during pregnancy
192 identified in the three-year period in the study areas

193 S_j = Number of stillbirths delivered by a mother with acute jaundice during pregnancy in the
194 surveillance hospitals

195 S_e = Number of stillbirths delivered by a mother with acute HEV during pregnancy in the
196 surveillance hospitals

197 N = Number of neonatal deaths born to a mother with acute jaundice during pregnancy
198 identified in the three-year period in the study areas

199 N_j = Number of neonatal deaths born to a mother with acute jaundice during pregnancy in the
200 surveillance hospitals

201 N_e = Number of neonatal deaths born to a mother with acute HEV during pregnancy in the
202 surveillance hospitals

203

204 We used non-parametric bootstrapping²⁶ to estimate the 95% confidence intervals for hepatitis
205 E associated mortality for the population aged ≥ 14 years. The 95% confidence intervals for
206 maternal mortality, stillbirth and neonatal mortality associated with HEV infection were
207 calculated by multiplying the lower and upper bounds of the jaundice associated mortality in
208 the hospital catchment areas by the respective lower and upper bounds of the proportion of
209 HEV infection among acute jaundice deaths in the study hospitals. The 95% confidence interval
210 of the proportion of hepatitis E among acute jaundice deaths in the study hospitals was
211 calculated by using the Wilson method for a binomial distribution²⁷, and the 95% confidence
212 interval for jaundice associated deaths in the hospital catchment areas was calculated using the
213 confidence interval for the mean of a Poisson distribution. We performed a sensitivity analysis
214 to check how the estimates of HEV-associated mortality vary when restricted to a two-year and
215 one-year recall period.

216 **Population mortality estimates**

217 The hepatitis E-associated mortality estimates generated from the study hospitals and the
218 mortality surveys in the hospital catchment areas were considered representative of the
219 hospital catchment areas, and with surveillance hospitals covering 5 out of 7 administrative
220 divisions, we expected that results could be extrapolated to the whole country (Figure 1). The
221 rural to urban population ratio of our study matched the national ratio, which was important

222 because urbanicity is a known risk factor for HEV infection²³. We, therefore, used our morality
223 estimates to extrapolate the total number of HEV-associated deaths among the population aged
224 ≥ 14 years, maternal deaths associated with HEV, stillborn babies and live born babies who died
225 during the neonatal period delivered by mothers with acute HEV infection in pregnancy in 2014
226 in Bangladesh.

227 **Ethical approval and consent**

228 The study protocol was reviewed and approved by the institutional review board of the icddr,b
229 (Protocol # PR-14060). In the surveillance hospitals, written informed consent was obtained
230 from patients over 17 years. For patients aged 14-17 years, assent was taken from the patients
231 and written consent from their parents. Written consent was sought from their guardians or
232 accompanying attendants if the patients were unable to provide consent themselves because of
233 illness. In the mortality survey in the hospital catchment areas, written consent was obtained
234 from a family member of the deceased directly involved in caregiving during the illness period.

235 **Results**

236 **Deaths among hospitalized acute jaundice patients**

237 In the six study hospitals, 1,925 acute jaundice patients were identified during December 2014
238 to September 2017; all patients consented for enrolment. Of them, 1,765 patients (92%;
239 including 173 pregnant women) were followed-up during hospitalization and three months
240 post-discharge. Among these patients, 302 died (17%), including 27 maternal deaths, and 28 of
241 these deaths (9%; 95% CI: 6%-13%) tested positive for IgM anti-HEV. Among the maternal
242 deaths, 8 cases (30%; 95% CI: 16%-49%) were positive for IgM anti-HEV (Table 1).

243 Among the 173 pregnant women followed, 125 (72%) had live births, 27 (16%) experienced
244 stillbirths, 11 (6%) had miscarriages, and 10 (6%) women died before the pregnancy outcome.
245 Of the enrolled pregnant women, 66 (38%) tested positive for IgM anti-HEV. Six (22%; 95% CI:
246 11%-41%) of the 27 stillbirths were delivered by mothers with IgM anti-HEV positivity. Among
247 the live births, 15 (12%) died within 28 days of their birth (neonatal deaths). Ten (67%; 95% CI:
248 42%-85%) of the 15 neonatal deaths were born to mothers who were positive for IgM anti-HEV.

249 **Acute jaundice deaths in the hospital catchment areas**

250 In the catchment areas of study hospitals, the team identified 33,794 deaths among persons
251 aged ≥ 14 years who died in the three years prior to the date of survey (Table 2). Among these,
252 277 (0.8%) were maternal deaths. Of the maternal deaths, 25 (9%) had acute jaundice, and of
253 the non-maternal deaths, 587 (1.7%) had acute jaundice prior to death. There were 57 stillbirths
254 and 53 neonatal deaths delivered by mothers with acute jaundice during pregnancy identified.

255 **Demographic characteristics of acute jaundice deaths**

256 *Surveillance hospitals:* Among non-maternal acute jaundice deaths, about two-thirds were
257 males, and one-third were aged ≥ 60 years (Table 3). Eighty-two percent resided in rural areas,
258 and 40% did no formal education. In most cases (72%), jaundice duration before hospitalization
259 was less than one month, and over three-quarters of the deaths occurred at home post-
260 discharge.

261 *Hospital catchment areas:* The sex ratio of acute jaundice deaths identified in the hospital
262 catchment areas was similar to those in the surveillance hospitals ($p=0.288$) (Table 3). However,
263 the patients who died in the hospital catchment areas were older than the patients who died
264 after enrolment in the hospital surveillance study ($p < 0.001$).

265 **Population-based estimate of HEV associated mortality**

266 In the 91 unions selected from the catchment areas of six study hospitals, the projected
267 population aged ≥ 14 years was approximately 1.6 million, and the projected number of live
268 births was 52,326 in 2014 (Appendix 1). We estimated HEV-associated mortality as 0.9 (95% CI:
269 0.6-1.3) per 100,000 population aged ≥ 14 years (Table 4). The maternal mortality ratio
270 associated with HEV was estimated as 4.7 (95% CI: 1.6-11.4) per 100,000 live births. We
271 estimated the HEV associated stillbirth rate as 8.1 (95% CI: 2.9-19.2) and neonatal mortality rate
272 as 22.5 (95% CI: 10.5-34.5) per 100,000 live births. We extrapolated these estimates to the
273 whole population of Bangladesh and estimated that in 2014 there were 986 (95% CI: 599-1338)
274 HEV-associated deaths among the population aged ≥ 14 years including 163 (95% CI: 57-395)
275 maternal deaths. Additionally, we estimated 279 (95% CI: 101-664) stillbirths and 780 (95% CI:
276 365-1,297) neonatal deaths associated with HEV infection in 2014 in Bangladesh.

277 In the sensitivity analysis for a two-year recall period, the estimated annual number of HEV-
278 associated deaths were 1,114 (95% CI: 634-1,584) for population aged ≥ 14 years (including 186
279 (95% CI: 60-476) maternal deaths), 375 (95% CI: 133-904) stillbirths and 780 (95% CI: 337-1,367)
280 neonatal deaths (Appendix 2). For one year recall period, the estimated number of HEV-
281 associated annual deaths were 1,101 (95% CI: 422-1,901) for population aged ≥ 14 years
282 (including 177 (95% CI: 43-548) maternal deaths), 412 (95% CI: 131-1092) stillbirths and 927
283 (95% CI: 359-1802) neonatal deaths.

284 **Discussion**

285 This study provides the first measured estimate of HEV associated mortality in Bangladesh by
286 combining data from a mortality survey covering a population of over 2.3 million and hospital-
287 based acute jaundice surveillance in six hospitals across the country. In the absence of any
288 reported HEV outbreak in Bangladesh during 2013-2015, we estimated that HEV infection
289 accounted for 1766 (95% CI: 964-2635) deaths annually, including pregnant women and
290 neonates. Additionally, we estimated 279 stillbirths per year, which are excluded from global
291 burden of disease estimates⁷, despite their significant physical and psychological toll. Preventing
292 HEV infections during pregnancy could prevent an estimated 1,222 maternal and neonatal
293 deaths and stillbirths annually. This population-based estimate of HEV mortality in Bangladesh
294 can inform the cost-effectiveness of HEV vaccination and other control measures to help
295 prioritise public health interventions.

296 The Global Burden of Disease (GBD) studies provide estimates of global and country-level
297 disease burdens, including hepatitis E, by employing models based on available data from vital
298 registration, surveillance, and verbal autopsy⁷. Most recently, the 2019 GBD study estimated that
299 there were 1,932 HEV-associated deaths globally in 2019⁷, which appears to be a significant
300 underestimate as we identified approximately this many deaths in Bangladesh alone. The HEV
301 mortality estimate by GBD studies appears to be sharp reduction, from 70,000 in 2005, 50,000 in
302 2013, 26,100 in 2016 and 14,700 in 2017³⁻⁶. This sudden decrease is likely due to methodological
303 changes in calculation and the use of different data sources across various GBD studies. For
304 instance, GBD studies transitioned from a single cause-of-death ensemble model (CODEm) to a
305 two-model hybrid approach in 2013, incorporating a global CODEm model and a CODEm model

306 limited to data-rich countries^{3,4,7}. Moreover, GBD 2019 considered location- and year-specific
307 factors for virus-specific case fatality rates⁷.

308 The 2013 global burden of disease study estimated 38,738 viral hepatitis deaths (25
309 deaths/100,000 population) in Bangladesh, with 12.7% attributed to HEV, totalling 4,920 HEV-
310 associated deaths⁴. However, subsequent GBD studies conducted in 2017 and 2019 reported
311 significantly lower figures of 227 and 111 HEV-associated deaths, respectively^{6,7}. These
312 variations and model uncertainties have left decision-makers hesitant on efficient vaccine
313 implementation.

314 We note a number of study limitations. First, in the hospital catchment areas, the signs of
315 jaundice among deaths were not verified by medical professionals; instead, caregivers reported
316 symptoms of jaundice in decedents who had passed away within 3 years of the survey. Although
317 our trained field team explained jaundice symptoms, and laypersons can identify eye yellowing
318 when pronounced, misclassification may have occurred. This limitation is common in mortality
319 surveys using the verbal autopsy method. Second, conducting interviews with caregivers
320 promptly is crucial for accurate cause-of-death identification, as delays between death and the
321 survey may introduce bias in reported symptoms²⁸. Our sensitivity analysis showed slightly
322 lower number of identified jaundice-associated deaths in the third year preceding the survey
323 compared to the first two years. While uncertain if this reflects a true change in burden or
324 random fluctuation, we provided separate estimations for HEV-associated deaths based on the
325 one and two years recall periods, illustrating how estimates vary when restricting recall bias
326 (Appendix 2). Third, while the Wantai IgM anti-HEV ELISA test is widely accepted as highly
327 sensitive for diagnosing acute HEV infections, a study by Huang et al. observed that about 3% of
328 acute viral hepatitis cases were negative for IgM anti-HEV but had a 4-fold rise in IgG anti-HEV in
329 their convalescent sera, indicating potential underestimation in our prevalence estimates due to
330 the test's sensitivity²⁹. Fourth, our assessment of HEV mortality in Bangladesh did not account
331 for miscarriages, which is significant among pregnant women with HEV infection³⁰. Finally, this
332 study presents the HEV burden in Bangladesh based on data six to nine years old, which may not
333 precisely reflect the current situation. Nonetheless, there are no other measured estimates of
334 HEV mortality in Bangladesh, so our estimates remain useful. Since there have been no targeted
335 strategies to reduce HEV transmission since this study, it is unlikely that there has been a
336 significant change in HEV burden in Bangladesh over this period.

337 This study provides a dependable estimate of HEV associated mortality in Bangladesh in the
338 absence of reliable data on HEV associated mortality in Bangladesh or in any region of the
339 world¹¹. Data from this study highlight the substantial underestimates of HEV deaths globally,
340 based on the latest global burden of disease estimates published in 2020⁷, suggesting that these
341 estimates should not be used for making decisions about global recommendations or policies.
342 Our data from Bangladesh can help determine the cost-effectiveness of vaccination against HEV
343 and other interventions, including improvement of drinking water quality, for national
344 policymakers, and our methods can be used by other countries requiring accurate HEV-
345 associated mortality estimates.

346

347 Disclaimer: The findings and conclusions in this report are those of the authors and do not
348 necessarily reflect the official position of the Centers for Disease Control and Prevention, or the
349 authors' affiliated institutions.


350

351 References

- 352 1. Aggarwal R, Jameel S. Hepatitis E. *Hepatology* 2011; **54**(6): 2218-26.
- 353 2. Khuroo MS. Study of an epidemic of non-A, non-B hepatitis. Possibility of another human
354 hepatitis virus distinct from post-transfusion non-A, non-B type. *Am J Med* 1980; **68**(6): 818-24.
- 355 3. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E
356 virus genotypes 1 and 2 in 2005. *Hepatology* 2012; **55**(4): 988-97.
- 357 4. Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to
358 2013: findings from the Global Burden of Disease Study 2013. *The Lancet* 2016; **388**(10049): 1081-8.
- 359 5. Collaborators GBDCoD. Global, regional, and national age-sex specific mortality for 264 causes of
360 death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2017;
361 **390**(10100): 1151-210.
- 362 6. Collaborators GBDCoD. Global, regional, and national age-sex-specific mortality for 282 causes of
363 death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease
364 Study 2017. *Lancet* 2018; **392**(10159): 1736-88.
- 365 7. Diseases GBD, Injuries C. Global burden of 369 diseases and injuries in 204 countries and
366 territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020;
367 **396**(10258): 1204-22.
- 368 8. Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine.
369 *N Engl J Med* 2007; **356**(9): 895-903.
- 370 9. Li SW, Zhang J, Li YM, et al. A bacterially expressed particulate hepatitis E vaccine: antigenicity,
371 immunogenicity and protectivity on primates. *Vaccine* 2005; **23**(22): 2893-901.
- 372 10. World Health Organization. Hepatitis E vaccines background paper: Strategic Advisory Group of
373 Experts (SAGE) on Immunization meeting. 2024. [Cited June 14, 2024]. Available from: chrome-
374 extension://efaidnbmnnnibpcajpcglclefindmkaj/[https://cdn.who.int/media/docs/default-](https://cdn.who.int/media/docs/default-source/immunization/sage/2024/march/hepatitis_e_background_paper_sage_mar24.pdf?sfvrsn=e14438c4_1)
375 [source/immunization/sage/2024/march/hepatitis_e_background_paper_sage_mar24.pdf?sfvrsn=e1443](https://cdn.who.int/media/docs/default-source/immunization/sage/2024/march/hepatitis_e_background_paper_sage_mar24.pdf?sfvrsn=e14438c4_1)
376 [8c4_1](https://cdn.who.int/media/docs/default-source/immunization/sage/2024/march/hepatitis_e_background_paper_sage_mar24.pdf?sfvrsn=e14438c4_1) 2024.
- 377 11. World Health Organization. Meeting of the Strategic Advisory Group of Experts on immunization,
378 October 2014 – conclusions and recommendations. [Cited December 03, 2017]. Available from:
379 [http://apps.who.int/iris/bitstream/handle/10665/242296/WER8950_561-](http://apps.who.int/iris/bitstream/handle/10665/242296/WER8950_561-576.PDF?sequence=1&isAllowed=y)
380 [576.PDF?sequence=1&isAllowed=y](http://apps.who.int/iris/bitstream/handle/10665/242296/WER8950_561-576.PDF?sequence=1&isAllowed=y).
- 381 12. Paul RC, Nazneen A, Banik KC, et al. Hepatitis E as a cause of adult hospitalization in Bangladesh:
382 Results from an acute jaundice surveillance study in six tertiary hospitals, 2014-2017. 2020; **14**(1):
383 e0007586.
- 384 13. Murray CJ, Lopez AD, Barofsky JT, Bryson-Cahn C, Lozano R. Estimating population cause-specific
385 mortality fractions from in-hospital mortality: validation of a new method. *PLoS Med* 2007; **4**(11): e326.
- 386 14. Bangladesh Bureau of Statistics. Bangladesh population and housing census 2011. [Cited May 18,
387 2024]. Available from: [http://www.bbs.gov.bd/site/page/47856ad0-7e1c-4aab-bd78-](http://www.bbs.gov.bd/site/page/47856ad0-7e1c-4aab-bd78-892733bc06eb/Population-and-Housing-Census)
388 [892733bc06eb/Population-and-Housing-Census](http://www.bbs.gov.bd/site/page/47856ad0-7e1c-4aab-bd78-892733bc06eb/Population-and-Housing-Census).
- 389 15. Chow S-C, Shao J, Wang H, Lohknygina Y. Sample size calculations in clinical research: CRC press;
390 2017.
- 391 16. Daniel WW. A foundation for analysis in the health sciences. *Biostatistics Toronto, John Wiley &*
392 *Sons* 1991: 209-15.
- 393 17. Gurley ES, Halder AK, Streatfield PK, et al. Estimating the burden of maternal and neonatal
394 deaths associated with jaundice in Bangladesh: possible role of hepatitis E infection. *Am J Public Health*
395 2012; **102**(12): 2248-54.
- 396 18. National Institute of Population Research and Training (NIPORT), MEASURE Evaluation, ICDDR,B.
397 Bangladesh maternal mortality and health care survey 2010. Dhaka, Bangladesh: NIPORT, MEASURE
398 Evaluation, and ICDDR,B. 2012. [Cited April 21, 2017]. Available from:
399 <https://www.measureevaluation.org/resources/publications/tr-12-87>.
- 400 19. National Institute of Population Research and Training (NIPORT), Mitra and Associates, ICF
401 International. Bangladesh Demographic and Health Survey 2014. Dhaka, Bangladesh, and Rockville,

- 402 Maryland, USA: NIPORT, Mitra and Associates, and ICF International. [Cited July 28, 2018]. Available
403 from: <https://dhsprogram.com/pubs/pdf/FR311/FR311.pdf>, 2016.
- 404 20. Yates F, Grundy PM. Selection without replacement from within strata with probability
405 proportional to size. *Journal of the Royal Statistical Society Series B (Methodological)* 1953: 253-61.
- 406 21. World Health Organization. International statistical classification of diseases and related health
407 problems, tenth revision. Geneva: World Health Organization. 1992.
- 408 22. Paul RC, Gidding HF, Nazneen A, et al. A Low-Cost, Community Knowledge Approach to Estimate
409 Maternal and Jaundice-Associated Mortality in Rural Bangladesh. *Am J Trop Med Hyg* 2018; **99**(6): 1633-
410 8.
- 411 23. Bangladesh Bureau of Statistics. Bangladesh population and housing census 2011- Urban area
412 report. 2014. [Cited December 23, 2018]. Available from:
413 [http://203.112.218.65:8008/WebTestApplication/userfiles/Image/National%20Reports/Population%20%
414 20Housing%20Census%202011.pdf](http://203.112.218.65:8008/WebTestApplication/userfiles/Image/National%20Reports/Population%20%20Housing%20Census%202011.pdf).
- 415 24. Bangladesh Bureau of Statistics. Sample vital registration system, 2013. [Cited July 02, 2017].
416 Available from:
417 http://203.112.218.65/WebTestApplication/userfiles/Image/LatestReports/MSVSB_Report_2013.pdf.
- 418 25. Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. *N Engl J Med* 2012; **367**(13): 1237-44.
- 419 26. Efron B, Tibshirani RJ. An introduction to the bootstrap: CRC press; 1994.
- 420 27. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. *Statistical science*
421 2001: 101-17.
- 422 28. Mirza NM, Macharia W, Wafula E, Agwanda R, Onyango F. Verbal autopsy: a tool for determining
423 cause of death in a community. *East Afr Med J* 1990; **67**(10): 693-8.
- 424 29. Huang S, Zhang X, Jiang H, et al. Profile of acute infectious markers in sporadic hepatitis E. *PLoS*
425 *One* 2010; **5**(10): e13560.
- 426 30. Heemelaar S, Hangula AL, Chipeio ML, et al. Maternal and fetal outcomes of pregnancies
427 complicated by acute hepatitis E and the impact of HIV status: A cross-sectional study in Namibia. *Liver*
428 *Int* 2022; **42**(1): 50-8.
- 429

430 **Figure 1: Map of Bangladesh showing the acute jaundice surveillance sites and the selected**
431 **areas (sub-districts) for mortality survey, December 2014- September 2017**



432

433

434 **Table 1: Hepatitis E cases among patients with acute jaundice who died during hospitalization**
 435 **or within three months of hospital discharge in six tertiary hospitals in Bangladesh, December**
 436 **2014–September 2017**

Characteristics	Patients with acute jaundice who died* (N=302)	IgM Anti-HEV Positive (N=28)	
		n	Percent (95% CI)
Maternal deaths	27	8	29.6 (15.8-48.5)
Non-maternal deaths	275	20	7.2 (4.8-11.0)
Sex			
Male	178	13	7.3 (4.3-12.1)
Female	97	7	7.2 (3.5-14.2)
Age group			
14-44 years	96	14	14.6 (8.9-23.6)
45-59 years	86	3	3.5 (1.2-9.8)
60+ years	93	3	3.2 (1.1-9.1)

437 * Defined as new onset of either yellow eyes or skin during the past 3 months, continuing
 438 on the day of admission.
 439

440

441

442 **Table 2: Deaths associated with acute jaundice in the catchment areas of the six surveillance**
 443 **hospitals, Bangladesh during the three-year period prior to the survey (Survey period:**
 444 **November 2014–February 2017)**

Characteristics	Deaths aged ≥ 14 years		Total
	Maternal deaths	Non-maternal deaths	
Deaths identified in the study areas*	277	33,517	33,794
Deaths with jaundice [†] prior to death	28 (10.1%) [95% CI: 7.0%-14.2%]	778 (2.3%) [95% CI: 2.2%-2.5%]	806 (2.4%) [95% CI: 2.2%-2.6%]
Deaths with acute jaundice [‡] prior to death	25 (9.0%) [95% CI: 6.1%-12.9%]	587 (1.7%) [95% CI: 1.6%-1.9%]	612 (1.8%) [95% CI: 1.7%-1.9%]

445 * There were two more maternal deaths for whom their caregivers refused to participate in this study.

446 † Defined as having yellow eyes or skin prior to death

447 ‡ Defined as new onset of either yellow eyes or skin during the 3 months prior to death

448

449 **Table 3: Demographic characteristics of enrolled patients with acute jaundice in the study**
 450 **hospitals who died during hospitalization or within three months of hospital discharge and**
 451 **identified deaths associated with acute jaundice in the hospital catchment areas during the**
 452 **three-year period prior to the survey**

Characteristics	Deaths* in hospitals			Deaths* in hospital catchment areas			P-value†
	Maternal	Non-maternal	Total	Maternal	Non-maternal	Total	
	N=27 n (%)	N=275 n (%)	N=302 n (%)	N=25 n (%)	N=587 n (%)	N=612 n (%)	
Sex							0.288
Male	-	178 (65)	178 (59)	-	383 (65)	383 (63)	
Female	27 (100)	97 (35)	124 (41)	25 (100)	204 (35)	229 (37)	
Age in years							<0.001
14-44	27 (100)	96 (35)	123 (41)	25 (100)	158 (27)	183 (30)	
45-59	0	86 (31)	86 (29)	0	160 (27)	160 (26)	
≥ 60	0	93 (34)	93 (31)	0	269 (46)	269 (44)	
Area of residence							0.036
Rural	17 (63)	232 (84)	249 (82)	19 (76)	517 (88)	536 (88)	
Urban	10 (37)	43 (16)	53 (18)	6 (24)	70 (12)	76 (12)	
Education							<0.001
None	4 (15)	118 (43)	122 (40)	5 (20)	306 (52)	311 (51)	
Class 1-4	8 (30)	72 (26)	80 (27)	3 (12)	61 (10)	64 (11)	
Class 5-9	9 (33)	55 (20)	64 (21)	16 (64)	160 (27)	176 (29)	
Class 10 or more	6 (22)	30 (11)	36 (12)	1 (4)	49 (8)	50 (8)	
Unknown	0	0	0	0	11 (2)	11 (2)	
Duration of jaundice at the time of death							0.002
≤ 1 month	21 (78)	197 (72)	218 (72)	16 (64)	356 (61)	372 (61)	
1< and ≤ 2 months	5 (19)	49 (18)	54 (18)	1 (4)	138 (24)	139 (23)	
> 2 and ≤ 3 months	1 (4)	29 (11)	30 (10)	8 (32)	93 (16)	101 (17)	
Sought care from a qualified health care provider‡							
First visit	-	-	-	15 (60)	343	358 (59)	
First or second visit	-	-	-	20 (80)	481	501 (82)	
Any visit	-	-	-	21 (84)	544	565 (92)	
Place of death							0.103
Health facility	14 (52)	51 (19)	65 (22)	15 (60)	85	100 (16)	
Home	13 (48)	224 (81)	237 (78)	7 (28)	480	487 (80)	
In-transit				3 (12)	22	25 (4)	

453 * Among persons aged ≥ 14 years

454 † Chi-squared test comparing total deaths in hospitals and hospital catchment areas by patients' characteristics

455 ‡ Health facility/qualified medical doctor/paramedic/nurse

456 **Table 4: Estimation of HEV associated mortality in the catchment areas of six acute jaundice**
457 **surveillance hospitals in Bangladesh, 2014**

Mortality estimation (indicators)	N
<i>Estimated population and live births in the hospital catchment areas</i> (projected for 2014; Appendix 1)	
Population aged ≥ 14 years [<i>P</i>]	1,595,697
Live births [<i>B</i>]	52,326
<i>Surveillance hospitals</i>	
Maternal deaths	
Maternal deaths with acute jaundice [<i>J_m</i>]	27
HEV cases among maternal deaths with acute jaundice [<i>E_m</i>] (95% CI)	8 (4-13)
Non-maternal deaths	
Non-maternal deaths with acute jaundice [<i>J</i>]	275
HEV cases among non-maternal deaths with acute jaundice [$\sum E_i$] (95% CI)	20 (13-30)
Stillbirths	
Stillbirths delivered by mothers with acute jaundice [<i>S_j</i>]	27
Stillbirths delivered by HEV positive mothers [<i>S_e</i>] (95% CI)	6 (3-11)
Neonatal deaths	
Neonatal deaths born to mothers with acute jaundice [<i>N_j</i>]	15
Neonatal death cases born to HEV positive mothers [<i>N_e</i>] (95% CI)	10 (6-13)
<i>Hospital catchment areas</i>	
Maternal deaths with acute jaundice [<i>D_m</i>] (95% CI)	25 (16-37)
Non-maternal deaths with acute jaundice [<i>D</i>] (95% CI)	587 (401-772)
¹ Expected number of non-maternal HEV deaths $\sum D_i \frac{E_i}{J_i}$	37
Stillbirths delivered by mothers with acute jaundice [<i>S</i>] (95% CI)	57 (43-74)
Neonatal deaths delivered by mothers with acute jaundice [<i>N</i>] (95% CI)	53 (40-69)
HEV associated mortality	
HEV associated mortality per 100,000 population aged ≥ 14 years (95% CI)	0.93 (0.6-1.3)
Maternal mortality ratio due to HEV per 100,000 live-births (95% CI)	4.7 (1.6-11.4)
Stillbirth rate due to HEV per 100,000 live-births (95% CI)	8.1 (2.9-19.2)
Neonatal mortality rate due to HEV per 100,000 live-births (95% CI)	22.5 (10.5-37.5)

458 ¹The expected number of non-maternal HEV-associated deaths for a specific age group in the hospital catchment areas was
459 calculated by multiplying the number of non-maternal jaundice-associated deaths in the hospital catchment areas by the
460 proportion of HEV-associated cases among non-maternal jaundice-associated deaths in the surveillance hospitals for that age
461 group. For instance, for the 15-44 age group, there were 158 jaundice-associated non-maternal deaths in the catchment areas
462 (Table 3), and the proportion of HEV-associated deaths among non-maternal deaths in that age-group in the surveillance
463 hospitals was 14.6% (Table 3), yielding an expected number of HEV-associated deaths in the catchment areas of 23.07 (i.e., 158 x
464 0.146).